Search results
Results from the WOW.Com Content Network
In drug development, serious adverse event (SAE) is defined as any untoward medical occurrence during a human drug trial that at any dose Results in death; Is life-threatening; Requires inpatient hospitalization or causes prolongation of existing hospitalization; Results in persistent or significant disability/incapacity
Adverse events categorized as "serious" (results in death, illness requiring hospitalization, events deemed life-threatening, results in persistent or significant incapacity, a congenital anomaly or medically important condition) must be reported to the regulatory authorities immediately, whereas non-serious adverse events are merely documented ...
Also known as AE (adverse event) or SAE (serious AE) reporting from clinical trials, safety information from clinical studies is used to establish a drug's safety profile in humans and is a key component that drug regulatory authorities consider in the decision-making as to whether to grant or deny market authorization (market approval) for a drug.
An adverse event (AE) refers to any unexpected and inappropriate occurrence at the time a drug is used, whether or not the event is associated with the administration of the drug. [1]: 1.2 Adverse Event (AE) An ADR is a special type of AE in which a causative relationship can be shown. [3] ADRs are only one type of medication-related harm.
Generally, any event which causes death, permanent damage, birth defects, or requires hospitalization is considered a serious adverse event. [4] The results of trials are often included in the labelling of the medication to provide information both for patients and the prescribing physicians.
The clinical hold was initiated following the Company's submission of a serious adverse event (SAE) and temporary enrollment halt to the FDA and other regulatory agencies. To date, three patients ...
The Leapfrog Group has announced that they will work with hospitals, health plans and consumer groups to advocate reducing payment for "never events", and will recognize hospitals that agree to certain steps when a serious avoidable adverse event occurs in the facility, including notifying the patient and patient safety organizations, and ...
By Christy Santhosh (Reuters) -The U.S. health regulator has placed a clinical hold on Iovance Biotherapeutics' trial of its experimental cell therapy in lung cancer patients after a patient death ...